
Paolo Pertile

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5532824/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Should current criteria for detecting and repairing arteriovenous fistula stenosis be reconsidered? Interim analysis of a randomized controlled trial. Nephrology Dialysis Transplantation, 2014, 29, 179-187.	0.7	46
2	Optimal Bayesian Sequential Sampling Rules for the Economic Evaluation of Health Technologies. Journal of the Royal Statistical Society Series A: Statistics in Society, 2014, 177, 419-438.	1.1	30
3	A Bayesian Decision Theoretic Model of Sequential Experimentation with Delayed Response. Journal of the Royal Statistical Society Series B: Statistical Methodology, 2017, 79, 1439-1462.	2.2	28
4	Static and dynamic efficiency of irreversible health care investments under alternative payment rules. Journal of Health Economics, 2012, 31, 169-179.	2.7	26
5	The impact of managed entry agreements on pharmaceutical prices. Health Economics (United) Tj ETQq1 1 0.78	4314 rgBT 1.7	/Qyerlock 1
6	Late-stage pharmaceutical R&D and pricing policies under two-stage regulation. Journal of Health Economics, 2016, 50, 298-311.	2.7	15
7	Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition. Applied Health Economics and Health Policy, 2020, 18, 357-362.	2.1	15
8	An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography. International Journal of Health Care Finance and Economics, 2009, 9, 317-332.	1.2	13
9	Which valuedâ€based price when patients are heterogeneous?. Health Economics (United Kingdom), 2020, 29, 923-935.	1.7	13
10	The Dynamics of Pharmaceutical Regulation and R&D Investments. Journal of Public Economic Theory, 2017, 19, 121-141.	1.1	11
11	A large scale OLG model for the analysis of the redistributive effects of policy reforms. European Journal of Political Economy, 2017, 48, 104-127.	1.8	11
12	The timing of adoption of positron emission tomography: a real options approach. Health Care Management Science, 2009, 12, 217-227.	2.6	10
13	Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective. Health Economics (United Kingdom), 2013, 22, 1507-1514.	1.7	10
14	Two-part payments for the reimbursement of investments in health technologies. Health Policy, 2014, 115, 230-236.	3.0	10
15	<scp>Investment in Health Technologies in a Competitive Model with Real Options</scp> . Journal of Public Economic Theory, 2008, 10, 923-952.	1.1	8
16	Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy. Cost Effectiveness and Resource Allocation, 2015, 13, 15.	1.5	7
17	R&D and market size: Who benefits from orphan drug legislation?. Journal of Health Economics, 2021, 80, 102522.	2.7	6
18	Pricing Policies When Patients are Heterogeneous: A Welfare Analysis. SSRN Electronic Journal, 0, , .	0.4	3

PAOLO PERTILE

#	Article	IF	CITATIONS
19	Drug Prices and Incentives to Innovation by the Pharmaceutical Industry. , 2015, , 389-401.		3
20	Public Policies over the Life Cycle: A Large Scale OLG Model for France, Italy and Sweden. SSRN Electronic Journal, 2015, , .	0.4	2
21	Redistribution at the local level: the case of public childcare in Italy. International Review of Economics, 2016, 63, 359-378.	1.3	2
22	Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial. Clinical Trials, 2021, 18, 647-656.	1.6	2
23	Optimal sequential sampling with delayed observations and unknown variance. , 2015, , .		1
24	The fiscal disadvantage of young Italians: a new view on consolidation and fairness. Journal of Economic Inequality, 2015, 13, 27-51.	3.5	1
25	Static and Dynamic Efficiency of Irreversible Health Care Investments Under Alternative Payment Rules. SSRN Electronic Journal, 0, , .	0.4	1
26	Public health interventions: evaluating the economic evaluations. Journal of Public Health Research, 2013, 2, 21.	1.2	0
27	<scp>J</scp> ob sick leave: Detecting opportunistic behavior. Health Economics (United Kingdom), 2019, 28, 373-386.	1.7	0
28	Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition― Applied Health Economics and Health Policy, 2020, 18, 455-456.	2.1	0
29	A reply to "Who would benefit from average valueâ€based pricing?― Health Economics (United) Tj ETQq1 1	0.784314	4 rgBT /Over